<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Research-Updates | Qi Zhao Research Group</title><link>https://seqworld.com/tag/research-updates/</link><atom:link href="https://seqworld.com/tag/research-updates/index.xml" rel="self" type="application/rss+xml"/><description>Research-Updates</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Fri, 18 Sep 2026 00:00:00 +0000</lastBuildDate><image><url>https://seqworld.com/media/icon_hueb7a633fcfb3f7202c8c8fb1e21f19fa_804644_512x512_fill_lanczos_center_3.png</url><title>Research-Updates</title><link>https://seqworld.com/tag/research-updates/</link></image><item><title>AdvanTIG-203: results and biomarkers in esophageal cancer</title><link>https://seqworld.com/post/26-09-18-advantig-203/</link><pubDate>Fri, 18 Sep 2026 00:00:00 +0000</pubDate><guid>https://seqworld.com/post/26-09-18-advantig-203/</guid><description>&lt;p>&lt;strong>Nature Communications · Published 2026-09-18&lt;/strong>&lt;/p>
&lt;p>A randomized phase II trial evaluates dual checkpoint blockade and exploratory immune biomarkers in advanced esophageal squamous cell carcinoma.&lt;/p>
&lt;p>The 125-patient trial did not meet its primary objective-response endpoint. Adding ociperlimab to tislelizumab did not significantly improve efficacy. Exploratory analyses identified immune-inflamed signatures that warrant further investigation.&lt;/p>
&lt;p>&lt;strong>Qi Zhao&amp;rsquo;s role:&lt;/strong> Co-author, Sun Yat-sen University Cancer Center.&lt;/p>
&lt;p>&lt;a href="https://doi.org/10.1038/s41467-026-77705-8" target="_blank" rel="noopener">Read the paper&lt;/a> · &lt;a href="https://pubmed.ncbi.nlm.nih.gov/42901884/" target="_blank" rel="noopener">PubMed&lt;/a>&lt;/p>
&lt;p>Source: &lt;a href="https://pubmed.ncbi.nlm.nih.gov/42901884/" target="_blank" rel="noopener">publication record&lt;/a>. Checked on 19 November 2026.&lt;/p></description></item><item><title>Vitamin B5 and B–T cell interactions in gastric cancer</title><link>https://seqworld.com/post/26-08-05-vitamin-b5/</link><pubDate>Wed, 05 Aug 2026 00:00:00 +0000</pubDate><guid>https://seqworld.com/post/26-08-05-vitamin-b5/</guid><description>&lt;p>&lt;strong>Nature Communications · Published 2026-08-05&lt;/strong>&lt;/p>
&lt;p>Single-cell profiling links naïve B cells and vitamin B5 metabolism to immune responses in HER2-positive gastric cancer.&lt;/p>
&lt;p>Patient samples and cell experiments reveal changes in B–T cell interactions during immunochemotherapy. Vitamin B5 improved anti-PD-1 responses in mouse models; these findings do not establish a clinical benefit from supplementation in patients.&lt;/p>
&lt;p>&lt;strong>Qi Zhao&amp;rsquo;s role:&lt;/strong> Corresponding author, Sun Yat-sen University Cancer Center.&lt;/p>
&lt;p>&lt;a href="https://doi.org/10.1038/s41467-026-76239-3" target="_blank" rel="noopener">Read the paper&lt;/a> · &lt;a href="https://pubmed.ncbi.nlm.nih.gov/42686743/" target="_blank" rel="noopener">PubMed&lt;/a>&lt;/p>
&lt;p>Source: &lt;a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC13538391/" target="_blank" rel="noopener">publication record&lt;/a>. Checked on 19 November 2026.&lt;/p></description></item><item><title>Connecting cellular senescence and circadian programs in colorectal cancer</title><link>https://seqworld.com/post/26-06-03-senescence-circadian/</link><pubDate>Wed, 03 Jun 2026 00:00:00 +0000</pubDate><guid>https://seqworld.com/post/26-06-03-senescence-circadian/</guid><description>&lt;p>&lt;strong>Frontiers in Immunology · Published 2026-06-03&lt;/strong>&lt;/p>
&lt;p>A four-gene score connects senescence and circadian programs with prognosis and immune heterogeneity in colorectal cancer.&lt;/p>
&lt;p>The study combines public cohorts, single-cell analyses and experimental validation. Higher SCore was associated with poorer survival. NOX4 experiments support a redox and inflammatory component; broader immune and circadian interpretations remain hypothesis-generating.&lt;/p>
&lt;p>&lt;strong>Qi Zhao&amp;rsquo;s role:&lt;/strong> Co-author, Sun Yat-sen University Cancer Center.&lt;/p>
&lt;p>&lt;a href="https://doi.org/10.3389/fimmu.2026.1804974" target="_blank" rel="noopener">Read the paper&lt;/a> · &lt;a href="https://pubmed.ncbi.nlm.nih.gov/42317343/" target="_blank" rel="noopener">PubMed&lt;/a>&lt;/p>
&lt;p>Source: &lt;a href="https://pubmed.ncbi.nlm.nih.gov/42317343/" target="_blank" rel="noopener">publication record&lt;/a>. Checked on 19 November 2026.&lt;/p></description></item></channel></rss>